
First Quarter 2025
First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Thursday April 24, 2025
Press releases
May 21, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
May 1, 2025
Media Update: ATS: Sanofi showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Sustainability Statement 2024 (ESG Report)
XBRL Viewer URD 2024
XBRL Viewer 20F 2024
Registration Document 2024 (in French)